Plenary Session

Latest Episodes:

1.53 CALGB 50303, REMoDL-B, & REMS, Orphan Drug Act, and Role of the FDA with Dr. Ameet Sarpatwari Apr 11, 2019

Show notes

We begin this episode with a discussion of two recent clinical trials in lymphoma: CALGB 50303 and REMoDL-B, respectively published in the Journal of Clinical Oncology and The Lancet Oncology. We include a primer on the history of lymphoma and the development of R-CHOP. We follow that with an in-depth interview with Dr. Ameet Sarpatwari of the Harvard Medical School on Risk Evaluation and Mitigation Strategies (REMS), the Orphan Drug Act, and, broadly, the purpose of the US FDA. CALGB 50303: doi.org/10.1200/JCO.18.01994 REMoDL-B: doi.org/10.1016/S1470-2045(18)30935-5 Dr. Sarpatwari's online course: https://www.edx.org/course/the-fda-and-prescription-drugs-current-controversies-in-context Back us on Patreon! www.patreon.com/plenarysession

1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson Apr 04, 2019

Show notes

In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X Rivaroxaban: doi.org/10.1056/NEJMoa1814630 Apixaban: doi.org/10.1056/NEJMoa1814468 Back us on Patreon! www.patreon.com/plenarysession

1.51 BONUS! Study Time Reduction Using Surrogate End Points with Dr. Emerson Chen Apr 02, 2019

Show notes

In this BONUS episode, we sit down for a quick interview with Dr. Emerson Chen of OHSU on his recent paper in JAMA Internal Medicine on how using surrogate end points as opposed to overall survival for FDA approval for oncology drugs only results in a reduced drug development time of approximately 11 months. Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351 Back us on Patreon! www.patreon.com/plenarysession

1.50 Replacing RCTs, Physicians on Twitter, Open-Access, & Orthopedics with Dr. Kathryn Schabel Mar 29, 2019

Show notes

This week we tackle the recent paper published in the Journal of Clinical Oncology titled "Comparison of Population-Based Observational Studies With Randomized Trials in Oncology" as well as a couple papers lamenting physicians' use of Twitter and the open-access model for journal publishing. We end the episode with an in-depth interview with Dr. Kathryn Schabel of OHSU on orthopedic surgery and how she practices. Observational Studies vs RCTs: doi.org/10.1200/JCO.18.01074 Back us on Patreon! www.patreon.com/plenarysession

1.49 Student Questions, Boeing 737 Max, Pancreatic Surveillance, Leukemia Drugs with Dr. Elihu Estey Mar 22, 2019

Show notes

We begin this episode by answering questions from a med student who is a Plenary Session fan. We transition from there to a discussion of the recent news stories on the FAA's handling of the Boeing 737 Max controversy and how this reflects on other USA regulatory agencies like the FDA. After a critique of the recent paper "Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance" published in the Journal of Clinical Oncology, we end with an interview with Dr. Elihu Estey of the University of Washington on his 40 years of experience as an oncologist, the "Renaissance" of drugs for leukemia, and advice for trainees on how to approach career goals. Pancreatic Surveillance: doi.org/10.1200/JCO.18.01512 Back us on Patreon! www.patreon.com/plenarysession

1.48 Falsified Data in Meta-Analyses and the Expert Halo Effect with Dr. Stephanie Halvorson Mar 13, 2019

Show notes

This week we dive deep into an article in JAMA IM on falsified data in meta-analyses. We also discuss the recent JAMA viewpoint "Reducing the Expert Halo Effect on Pharmacy and Therapeutics Committees" with its author, Dr. Stephanie Halvorson of OHSU. Falsified data: doi.org/10.1001/jamainternmed.2014.7774 Expert Halo Effect: doi.org/10.1001/jama.2018.20789 Back us on Patreon! www.patreon.com/plenarysession

1.47 BONUS! Medical Reversal: Class Lecture Mar 11, 2019

Show notes

This BONUS episode is a lecture on medical reversal that was pre-recorded for a class at Harvard Medical School. The recording was played for students in February of 2019 and followed by a Q&A. The slides referenced are available to Patreon supporters. Back us on Patreon! www.patreon.com/plenarysession

1.46 BONUS! Personal Finances with Dr. Tom Beer Mar 08, 2019

Show notes

In this bonus episode, we bring back Dr. Tom Beer of OHSU from episode 1.33 to discuss how to manage your personal finances. The interview is aimed at young physicians, but there is something for all audiences as we cover a broad range of topics: paying off loans, optimizing retirement savings, buying a home, and investing. Back us on Patreon! www.patreon.com/plenarysession

1.45 Real-World Data, Gottlieb, & Using the EHR for Meaningful Improvement with Dr. Deborah Cohen Mar 06, 2019

Show notes

This week's episode begins with praise for the recent article by Booth CM, Karim S, and Mackillop WJ on real-world data published in Nature Reviews Clinical Oncology. Next, we tackle the resignation of Scott Gottlieb as FDA commissioner and how we can measure the success of the FDA. Finally, we have an interview with Dr. Deborah Cohen of OHSU on effective communication between the clinician and the patient and how we can use data from the Electronic Health Record to make meaningful improvements in care. Real-world data: doi.org/10.1038/s41571-019-0167-7 Back us on Patreon! www.patreon.com/plenarysession

1.44 BONUS! Screen Time and Children's Performance Mar 01, 2019

Show notes

This BONUS episode is the recording of a lecture given as part of the medical school class Appraising Medical Literature, taught at OHSU. This clip from the class critiques the recent JAMA Pediatrics paper "Association Between Screen Time and Children’s Performance on a Developmental Screening Test". Screen Time: doi.org/10.1001/jamapediatrics.2018.5056 Back us on Patreon! www.patreon.com/plenarysession

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected